A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects
Guangwen Liu(The Affiliated Hospital to Changchun University of Chinese Medicine), Haimiao Yang(The Affiliated Hospital to Changchun University of Chinese Medicine), Jinling Xue, Yingzi Cui(The Affiliated Hospital to Changchun University of Chinese Medicine), Qiaohuan Deng(Changchun University of Chinese Medicine), Zhongnan Xu, Xinyao Qu(The Affiliated Hospital to Changchun University of Chinese Medicine), Wanhua Wang(The Affiliated Hospital to Changchun University of Chinese Medicine), Wei Yang(University of Washington), Tianying Chang(The Affiliated Hospital to Changchun University of Chinese Medicine), Jiahui Chen(Xinjiang Medical University), Zeyu Wang(Anhui University), Yanli Wang(The Affiliated Hospital to Changchun University of Chinese Medicine), Shuang Yu(Heilongjiang University of Chinese Medicine), Qing Ren(Chinese University of Hong Kong), Yannan Zhou(The Affiliated Hospital to Changchun University of Chinese Medicine), Zhengzhi Liu(The Affiliated Hospital to Changchun University of Chinese Medicine)
Cited by 5
Related Papers
Glioma targeted therapy: insight into future of molecular approaches
|Molecular Cancer|2022|727
Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer
|Journal of Experimental & Clinical Cancer Research|2021|535
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts
|Journal of Hematology & Oncology|2022|273
Single-cell RNA-sequencing atlas reveals an MDK-dependent immunosuppressive environment in ErbB pathway-mutated gallbladder cancer
|Journal of Hepatology|2021|215
Inhibition of pulmonary fibrosis in mice by CXCL10 requires glycosaminoglycan binding and syndecan-4
|Journal of Clinical Investigation|2010|165